Abstract
Background. Evidence regarding the use of proton-pump inhibitors (PPIs) in COVID-19 patients remains elusive. Aim. To examine the potential effects of PPI use on the clinical outcomes of COVID-19 patients in a territory-wide cohort. Methods. A retrospective cohort study was performed using data from a territory-wide database in Hong Kong. Patients diagnosed with COVID-19 from 23 January 2020 to 1 January 2021 were identified by virological results. The primary endpoint was a composite of intensive care unit admission, use of invasive mechanical ventilation, and/or death. PPI users were identified by PPI use within 12 months prior to their diagnosis of COVID-19. Results. We identified 8,675 COVID-19 patients (mean age 46 years, 49% male, 97.6% of all reported cases in Hong Kong), of which 579 (6.7%) patients had used PPI. PPI users were found to be older, more likely to have comorbidities, concomitant medications and unfavourable laboratory parameters than nonusers. Of the 8,675 COVID-19 patients, 500 (5.8%) developed the primary endpoint. After propensity score (PS) balancing for patients’ demographics, comorbidities, laboratory parameters, and use of medications, PPI use was not found to be associated with the development of primary endpoint in PS weighting (weighted hazard ratio (HR) 1.10, 95% confidence interval (CI) 0.82–1.46, P = 0.529 ), and PS matching analysis (weighted HR 0.79, 95% CI 0.56–1.13, P = 0.198 ). Consistent nonassociation was observed after multivariable adjustment (adjusted HR 0.84, 95% CI 0.67–1.06, P = 0.142 ), and in subgroups of current and past PPI users. Conclusion. PPI use is not found to be associated with adverse clinical outcomes in COVID-19 patients. The result remains robust after PS weighting, PS matching, and multivariable adjustment.
Highlights
COVID-19, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has infected over 238 million people and caused over 4.8 million deaths worldwide as of 13 October 2021 [1]
As gastric acid can inhibit swallowed infectious microorganisms and prevent them from entering the intestine, pump inhibitors (PPIs) may alter its users’ susceptibility to enteric pathogens [9]. It was observed in an American online survey that the use of PPI increases the risks of contracting COVID-19 among community-dwelling people [10], whereas a separate Korean nationwide study suggested that PPI use does not increase users’ susceptibility to SARS-CoV-2 infection
We identified 8,675 COVID-19 patients between 23 January 2020 and 1 January 2021 which represented 97.6% of all patients who reported to the Department of Health during the study period
Summary
COVID-19, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has infected over 238 million people and caused over 4.8 million deaths worldwide as of 13 October 2021 [1]. As gastric acid can inhibit swallowed infectious microorganisms and prevent them from entering the intestine, PPI may alter its users’ susceptibility to enteric pathogens [9] It was observed in an American online survey that the use of PPI increases the risks of contracting COVID-19 among community-dwelling people [10], whereas a separate Korean nationwide study suggested that PPI use does not increase users’ susceptibility to SARS-CoV-2 infection. The association between famotidine use and better clinical outcomes for COVID-19 patients was not observed in a similar territory-wide study conducted in Hong Kong, after adjusting for patients’ concomitant medications and laboratory parameters [15]. The result remains robust after PS weighting, PS matching, and multivariable adjustment
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
